Company names starting with "V"

Patents whose numbers are in italics have been extended under 35 USC 156. Unless otherwise noted, all expiration dates include applicable Sec. 156 and pediatric (PED) extensions.


Valneva Austria GmbH
Ixiaro (Injection) (Intramuscular) Japanese Encephalitis Vaccine, Inactivated, Adsorbed
NDA Applicant: Valneva Austria GmbH      BLA No.: 125280  Prod. No.: 001 Rx (0.5ML)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityMay 17, 2020Orphan Designation: Prevention of Japanese encephalitis virus in pediatric patients.
Approved Labeled Indication: IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus (JEV). IXIARO is approved for use in individuals 2 months of age and older.
Exclusivity Protected Indication: To extend the age range to include infants, children, and adolescents 2 months to less than 17 years of age for active immunization for the prevention of disease caused by Japanese encephalitis virus.


Last edited: 19 August 2023
© 2001-2023 Bruce A. Pokras, All rights reserved worldwide